How does Leqvio compare to other cholesterol medications like statins or PCSK9 inhibitors?

Leqvio is an injectable treatment that may help lower LDL (“bad”) cholesterol, especially for people who can’t reach target levels with statins alone. It works differently from statins and is dosed less frequently than PCSK9 inhibitors.

Understanding Cholesterol Treatment Options

Many patients explore alternatives when statins aren’t enough or cause side effects. Leqvio is among newer cholesterol-lowering options and offers a different approach. Comparing Leqvio to statins and PCSK9 inhibitors involves looking at:

• How each medication works to lower LDL cholesterol
• Who may benefit and when Leqvio is recommended
• Dosing frequency and delivery method
• Safety profiles and availability

This helps explain why Leqvio may be chosen when other options aren’t effective or well tolerated.

How Leqvio Works Compared to Statins and PCSK9 Inhibitors

How it works

Leqvio (inclisiran) may work by targeting the production of PCSK9, a protein that reduces the liver’s ability to remove LDL cholesterol from the blood. According to the Leqvio drug profile on Drugs.com, this is done through RNA interference—preventing the creation of the PCSK9 protein at the source.

Statins, by contrast, reduce cholesterol production in the liver while increasing LDL receptors. PCSK9 inhibitor injections (like alirocumab and evolocumab) block the PCSK9 enzyme after it’s made, preventing it from disabling those receptors. All three strategies aim to lower LDL-C, but via different biological steps.

Clinical applications

Leqvio is approved for adults with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia who need further LDL-lowering therapy. It may be added when statins alone aren’t enough or not tolerated well. According to the Israeli Ministry of Health documentation, it’s administered just twice per year after an initial loading dose.

In contrast, most statins are taken daily, and PCSK9 inhibitors like Repatha or Praluent are injected every 2–4 weeks. Leqvio’s infrequent dosing may support better adherence for some patients.

Safety and Effectiveness

Safety profile

According to Drugs.com, the most commonly reported side effects of Leqvio include injection site reactions, joint pain, and chest cold symptoms. Serious reactions appear to be rare. Patients should be monitored for any allergic responses and liver enzyme issues, as with other lipid-lowering therapies.

FDA approval and indications

The FDA has approved Leqvio for use in people with ASCVD or heterozygous familial hypercholesterolemia who require additional LDL lowering. It is not a replacement for statins but can be added when needed. Regular cholesterol monitoring and medical oversight remain essential.

Access and Availability

How to obtain safely

IsraelPharm offers international access to Leqvio at competitive prices, making it an option for eligible patients seeking convenience and savings. It requires a prescription and provider oversight to ensure it’s the right fit for your treatment plan.

Always consult your healthcare provider before starting or switching cholesterol medications.

Key Takeaways

• Leqvio may help lower LDL cholesterol by reducing PCSK9 production via RNA interference.
• It is injected twice a year (after initial doses), offering a less frequent dosing schedule versus PCSK9 inhibitors.
• Statins work differently—reducing cholesterol production in the liver—but are often tried first.
• Leqvio may be considered when statins aren’t enough or well tolerated, under provider guidance.
• Available by prescription and offered through international pharmacies like IsraelPharm.

Frequently Asked Questions

Is Leqvio a statin?

No. Leqvio is not a statin—it uses RNA interference to reduce PCSK9 production, which helps lower LDL cholesterol through a different biological process.

How often do I need to get Leqvio injections?

After the first two doses (at month 0 and month 3), Leqvio is injected just twice a year. This sets it apart from other injectable cholesterol treatments.

Is Leqvio better than PCSK9 inhibitors like Repatha?

Leqvio and PCSK9 inhibitors both lower LDL cholesterol, but they work differently. Leqvio has the advantage of less frequent dosing, though choice depends on individual patient factors.

Who should consider Leqvio?

Adults with ASCVD or familial hypercholesterolemia who haven’t met LDL-C goals with statins may consider Leqvio, as recommended by their doctor.

How can I get Leqvio if it’s not available locally?

International pharmacies such as IsraelPharm can supply Leqvio globally, often at reduced costs and with professional support. A valid prescription is required.